BergenstalRM, AhmannAJ, BaileyT, BeckRW, BissenJ, BuckinghamB, DeebL, DolinRH, GargSK, GolandR, HirschIB, KlonoffDC, KrugerDF, MatfinG, MazzeRS, OlsonBA, ParkinC, PetersA, PowersMA, RodriguezH, SoutherlandP, StrockES, TamborlaneW, WesleyDM. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP)Diabetes Technol Ther, 2013; 15:198–211.
4.
Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. NathanDM, ZinmanB, ClearyPA, BacklundJY, GenuthS, MillerR, OrchardTJ. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications and Pittsburgh Epidemiology of Diabetes Complications experience (1983–2005)Arch Intern Med, 2009; 169:1307–1316.
5.
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med, 1993; 329:977–986.
6.
UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)Lancet, 1998; 352:854–865.
7.
DCCT/EDIC Research Group. de BoerIH, SunW, ClearyPA, LachinJM, MolitchME, SteffesMW, ZinmanB. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med, 2011; 365:2366–2376.
8.
Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA, 2003; 290:2159–2167.
9.
YauJW, RogersSL, KawasakiR, LamoureuxEL, KowalskiJW, BekT, ChenSJ, DekkerJM, FletcherA, GrauslundJ, HaffnerS, HammanRF, IkramMK, KayamaT, KleinBE, KleinR, KrishnaiahS, MayurasakornK, O'HareJP, OrchardTJ, PortaM, RemaM, RoyMS, SharmaT, ShawJ, TaylorH, TielschJM, VarmaR, WangJJ, WangN, WestS, XuL, YasudaM, ZhangX, MitchellP, WongTY. Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care, 2012; 35:556–564.
10.
KoenigRJ, PetersonCM, JonesRL, SaudekC, LehrmanM, CeramiA. Correlation of glucose regulation and hemoglobin A1c in diabetes mellitus. N Engl J Med, 1976; 295:417–420.
11.
CryerPE. Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II Diabetes. Diabetologia, 2002; 45:937–948.
12.
CryerPE. Severe hypoglycemia predicts mortality in diabetes. Diabetes Care, 2012; 35:1814–1816.
13.
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Effectiveness of continuous glucose monitoring in a clinical care environment: evidence from the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring (JDRF-CGM) Trial. Diabetes Care, 2010; 33:17–22.
14.
JDRF CGM Study Group. JDRF randomized clinical trial to assess the efficacy of real-time continuous glucose monitoring in the management of type 1 diabetes: research design and methods. Diabetes Technol Ther, 2008; 10:310–321.
15.
RuedyKJ, TamborlaneWV. The landmark JDRF continuous glucose monitoring randomized trials: a look back at the accumulated evidence: Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. J Cardiovasc Transl Res, 2012; 5:380–387.
16.
KowalskiAJ. Can we really close the loop, how soon? Accelerating the availability of an artificial pancreas: a roadmap to better diabetes outcomes. Diabetes Technol Ther, 2009; 11,(Suppl 1):S-113–S-119.
17.
HirschIB, BrownleeM. Should minimal blood glucose variability become the gold standard of glycemic control?J Diabetes Complications, 2005; 19:178–181.
18.
SiegelaarSE, HollemanF, HoekstraJB, DeVriesJH. Glucose variability; does it matter?Endocr Rev, 2010; 31:171–182.
19.
MonnierL, WojtusciszynA, ColetteC, OwensD. The contribution of glucose variability to asymptomatic hypoglycemia in persons with type 2 diabetes. Diabetes Technol Ther, 2011; 13:813–818.
20.
QuY, JacoberS, ZhangQ, WolkaL, DeVriesJH. Rate of hypoglycemia in insulin-treated patients with type 2 diabetes can be predicted from glycemic variability data. Diabetes Technol Ther, 2012; 14:1008–1012.
21.
WoodJR, MillerKM, MaahsDM, BeckRW, DimeglioLA, LibmanIM, QuinnM, TamborlaneWV, WoernerSE. T1D Exchange Clinic Network: Most youth with type 1 diabetes in the T1 D Exchange Clinic Registry do not meet American Diabetes Association or International Society for Pediatric Adolescent Diabetes clinical guidelines. Diabetes Care, 2013Jan22[Epub ahead of print]10.2337/dc12-1959.
22.
NimriR, AtlasE, AjzensztejnM, MillerS, OronT, PhillipM. Feasibility study of automated overnight closed-loop glucose control under MD-Logic artificial pancreas in patients with type 1 diabetes: the DREAM Project. Diabetes Technol Ther, 2012; 14:728–735.
23.
ElleriD, AllenJM, BiagioniM, KumareswaranK, LeelarathnaL, CaldwellK, NodaleM, WilinskaME, AceriniCL, DungerDB, HovorkaR. Evaluation of a portable ambulatory prototype for automated overnight closed-loop insulin delivery in young people with type 1 diabetes. Pediatr Diabetes, 2012; 13:449–453.
